BR112021004689A2 - conjugados glp-1 liberáveis - Google Patents
conjugados glp-1 liberáveis Download PDFInfo
- Publication number
- BR112021004689A2 BR112021004689A2 BR112021004689-5A BR112021004689A BR112021004689A2 BR 112021004689 A2 BR112021004689 A2 BR 112021004689A2 BR 112021004689 A BR112021004689 A BR 112021004689A BR 112021004689 A2 BR112021004689 A2 BR 112021004689A2
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- compound
- compound according
- group
- liraglutide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730341P | 2018-09-12 | 2018-09-12 | |
| US62/730,341 | 2018-09-12 | ||
| US201862730935P | 2018-09-13 | 2018-09-13 | |
| US62/730,935 | 2018-09-13 | ||
| US201862771972P | 2018-11-27 | 2018-11-27 | |
| US62/771,972 | 2018-11-27 | ||
| PCT/IB2019/057715 WO2020053815A1 (en) | 2018-09-12 | 2019-09-12 | Releasable glp-1 conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021004689A2 true BR112021004689A2 (pt) | 2021-06-08 |
Family
ID=68382464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021004689-5A BR112021004689A2 (pt) | 2018-09-12 | 2019-09-12 | conjugados glp-1 liberáveis |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11357828B2 (https=) |
| EP (1) | EP3849660A1 (https=) |
| JP (2) | JP7675648B2 (https=) |
| KR (1) | KR20210057130A (https=) |
| CN (1) | CN112955216A (https=) |
| AU (2) | AU2019340472A1 (https=) |
| BR (1) | BR112021004689A2 (https=) |
| CA (1) | CA3112473A1 (https=) |
| TW (1) | TWI834720B (https=) |
| WO (1) | WO2020053815A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190125310A (ko) * | 2017-03-10 | 2019-11-06 | 퀴아펙 파마슈티칼스 에이비 | 방출가능한 접합체 |
| CA3112473A1 (en) | 2018-09-12 | 2020-03-19 | Quiapeg Pharmaceuticals Ab | Releasable glp-1 conjugates |
| WO2022029178A1 (en) | 2020-08-05 | 2022-02-10 | Ascendis Pharma A/S | Conjugates comprising reversible linkers and uses thereof |
| CA3190399A1 (en) * | 2020-08-24 | 2022-03-03 | James M. Wilson | Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases |
| CN113430154A (zh) * | 2021-05-21 | 2021-09-24 | 深圳市前海金卓生物技术有限公司 | 分泌glp-1的蛋白表达系统及其制备方法和应用 |
| WO2024079739A1 (en) * | 2022-10-14 | 2024-04-18 | Bhami's Research Laboratory, Pvt. Ltd. | Polypeptide formulations for oral delivery |
| WO2024101446A1 (ja) * | 2022-11-10 | 2024-05-16 | ルクサナバイオテク株式会社 | 架橋部にグアニジノ構造を有する修飾ヌクレオシドおよびそれを用いたオリゴヌクレオチドの製造方法 |
| WO2024184351A1 (en) * | 2023-03-06 | 2024-09-12 | Ascendis Pharma A/S | Compounds of drugs with an albumin binding moiety |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4647447A (en) | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US5637684A (en) | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
| ES2285707T3 (es) | 1994-10-21 | 2007-11-16 | Nps Pharmaceuticals, Inc. | Compuestos activos frente al receptor de calcio. |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5817856A (en) | 1995-12-11 | 1998-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
| US5830600A (en) | 1996-05-24 | 1998-11-03 | Sri International | Nonflammable/self-extinguishing electrolytes for batteries |
| JPH10175987A (ja) | 1996-12-13 | 1998-06-30 | Nof Corp | 重合性基含有有機リン酸エステル化合物およびその製造方法 |
| US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| US5922897A (en) | 1998-05-29 | 1999-07-13 | Xerox Corporation | Surfactant processes |
| US20030165849A1 (en) | 2000-11-28 | 2003-09-04 | Biliang Zhang | Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of RNA |
| US6320041B1 (en) | 2001-04-13 | 2001-11-20 | Trilink Biotechnologies, Inc. | Pre-activated carbonyl linkers for the modification of oligonucleotides |
| US6743905B2 (en) | 2001-04-16 | 2004-06-01 | Applera Corporation | Mobility-modified nucleobase polymers and methods of using same |
| JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
| US20100240730A1 (en) | 2002-02-20 | 2010-09-23 | Merck Sharp And Dohme Corp. | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
| US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| AU2004212941B2 (en) | 2003-02-14 | 2011-05-26 | Quanta Biodesign, Ltd | The selective and specific preparation of discrete PEG compounds |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| WO2005077966A1 (en) | 2004-02-10 | 2005-08-25 | Isis Pharmaceuticals, Inc. | Substituted pixyl protecting groups for oligonucleotide synthesis |
| CA2940803A1 (en) | 2004-03-23 | 2005-10-27 | Ascendis Pharma Gmbh | Prodrug linker |
| EP1758575A1 (en) * | 2004-06-11 | 2007-03-07 | Novo Nordisk A/S | Counteracting drug-induced obesity using glp-1 agonists |
| US20060063147A1 (en) | 2004-09-21 | 2006-03-23 | Chernov Boris K | Omega-amino-PEG-phosphoramidites and conjugates thereof |
| TW200612993A (en) | 2004-10-08 | 2006-05-01 | Alza Corp | Lipopolymer conjugates |
| AU2006304856A1 (en) | 2005-10-21 | 2007-04-26 | Synageva Biopharma Corp. | Glycolated and glycosylated poultry derived therapeutic proteins |
| WO2007055789A2 (en) | 2005-10-31 | 2007-05-18 | Neose Technologies, Inc. | Expression of soluble therapeutic proteins |
| AU2006316903B8 (en) | 2005-11-23 | 2010-10-14 | F. Hoffmann-La Roche Ag | Polynucleotide labelling reagent |
| EP2364735A3 (en) | 2005-12-16 | 2012-04-11 | Nektar Therapeutics | Branched PEG conjugates of GLP-1 |
| JP5140824B2 (ja) | 2006-04-19 | 2013-02-13 | 国立大学法人 東京大学 | リゾホスファチジルスレオニンおよびその誘導体 |
| US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
| WO2008067127A2 (en) | 2006-11-09 | 2008-06-05 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
| US20130195888A1 (en) | 2007-11-30 | 2013-08-01 | Abbvie | Ultrafiltration and diafiltration formulation methods for protein processing |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| AU2009209565B2 (en) | 2008-02-01 | 2013-09-19 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| US8883211B2 (en) | 2008-07-10 | 2014-11-11 | Serina Therapeutics, Inc. | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
| EP2334335A1 (en) | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of cd-np peptides |
| PT2432489T (pt) | 2009-05-20 | 2016-12-07 | Biomarin Pharm Inc | Variantes do péptido natriurético de tipo c |
| WO2011012722A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Prodrugs containing an aromatic amine connected by an amido bond to a linker |
| US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| CN107129538B (zh) * | 2010-04-27 | 2021-07-16 | 西兰制药公司 | Glp-1受体激动剂和胃泌素的肽缀合物及其用途 |
| ES2584381T3 (es) | 2010-05-05 | 2016-09-27 | Prolynx Llc | Liberación controlada de compuestos activos desde conjugados macromoleculares |
| EP2600897A2 (en) | 2010-08-06 | 2013-06-12 | The Regents of the University of Colorado, A Body Corporate | Methods and compositions for the inhibition of fructokinase |
| CA3065178C (en) | 2010-12-13 | 2022-02-01 | Quiapeg Pharmaceuticals Ab | Functionalized polymers |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| CA2843506C (en) | 2011-08-12 | 2020-05-12 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
| CN102321170B (zh) * | 2011-09-14 | 2013-11-13 | 深圳翰宇药业股份有限公司 | 利拉鲁肽变构体及其缀合物 |
| AU2013276219B2 (en) | 2012-06-12 | 2018-03-08 | Quiapeg Pharmaceuticals Ab | Conjugates of biologically active molecules to functionalized polymers |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| KR102442906B1 (ko) * | 2013-12-19 | 2022-09-14 | 씨젠 인크. | 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커 |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| AU2015277100A1 (en) * | 2014-06-20 | 2017-02-02 | Abgenomics International Inc. | HER2 antibody-drug conjugates |
| JP6369721B2 (ja) | 2014-07-04 | 2018-08-08 | 国立大学法人 東京大学 | リゾホスファチジルセリン誘導体 |
| CN104725628B (zh) | 2014-10-01 | 2018-04-17 | 厦门赛诺邦格生物科技股份有限公司 | 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质 |
| EP3242689A1 (en) | 2015-01-09 | 2017-11-15 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs |
| CA2979895A1 (en) | 2015-03-18 | 2016-09-22 | Immunobiochem Corporation | Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens |
| CN107921030B (zh) | 2015-08-14 | 2024-07-02 | 荣昌生物制药(烟台)股份有限公司 | 抗体-药物偶联物的共价连接子及其制备方法与应用 |
| CA3007976C (en) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| DK3400019T3 (da) | 2016-01-08 | 2022-10-24 | Ascendis Pharma Growth Disorders As | CNP-prodrugs med bærerbinding ved ringenheden |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| KR20190125310A (ko) | 2017-03-10 | 2019-11-06 | 퀴아펙 파마슈티칼스 에이비 | 방출가능한 접합체 |
| BR102017004833A2 (pt) * | 2017-03-10 | 2018-10-30 | Leite Miguel | produto bactericida/germicida/fungicida/esporocida extraído dos ácidos graxos a ser administrado via oral em animais de criação monogástricos e/ou ruminantes e método de obtenção |
| KR20220127380A (ko) | 2018-03-09 | 2022-09-19 | 퀴아펙 파마슈티칼스 에이비 | 방출가능한 항체 접합체 |
| CA3112473A1 (en) | 2018-09-12 | 2020-03-19 | Quiapeg Pharmaceuticals Ab | Releasable glp-1 conjugates |
-
2019
- 2019-09-12 CA CA3112473A patent/CA3112473A1/en active Pending
- 2019-09-12 WO PCT/IB2019/057715 patent/WO2020053815A1/en not_active Ceased
- 2019-09-12 KR KR1020217010754A patent/KR20210057130A/ko not_active Ceased
- 2019-09-12 CN CN201980059931.XA patent/CN112955216A/zh active Pending
- 2019-09-12 JP JP2021513792A patent/JP7675648B2/ja active Active
- 2019-09-12 BR BR112021004689-5A patent/BR112021004689A2/pt not_active IP Right Cessation
- 2019-09-12 AU AU2019340472A patent/AU2019340472A1/en not_active Abandoned
- 2019-09-12 US US16/568,935 patent/US11357828B2/en active Active
- 2019-09-12 TW TW108133127A patent/TWI834720B/zh active
- 2019-09-12 EP EP19795047.0A patent/EP3849660A1/en active Pending
-
2021
- 2021-12-22 US US17/559,692 patent/US11957735B2/en active Active
-
2024
- 2024-02-16 US US18/444,317 patent/US20240181017A1/en active Pending
- 2024-10-10 AU AU2024227217A patent/AU2024227217A1/en not_active Abandoned
- 2024-10-17 JP JP2024182071A patent/JP2025023928A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024227217A1 (en) | 2024-10-31 |
| CA3112473A1 (en) | 2020-03-19 |
| US11357828B2 (en) | 2022-06-14 |
| KR20210057130A (ko) | 2021-05-20 |
| US20200108124A1 (en) | 2020-04-09 |
| AU2019340472A1 (en) | 2021-04-01 |
| US20220118055A1 (en) | 2022-04-21 |
| TWI834720B (zh) | 2024-03-11 |
| CN112955216A (zh) | 2021-06-11 |
| JP2025023928A (ja) | 2025-02-19 |
| EP3849660A1 (en) | 2021-07-21 |
| WO2020053815A1 (en) | 2020-03-19 |
| JP2021535920A (ja) | 2021-12-23 |
| JP7675648B2 (ja) | 2025-05-13 |
| US11957735B2 (en) | 2024-04-16 |
| TW202034947A (zh) | 2020-10-01 |
| US20240181017A1 (en) | 2024-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240181017A1 (en) | Releasable glp-1 conjugates | |
| US12274752B2 (en) | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | |
| CN105792852B (zh) | 葡萄糖响应性的胰岛素缀合物 | |
| CN112004928A (zh) | 寡核苷酸组合物及其使用方法 | |
| EP3992291B1 (en) | Novel compound and application thereof | |
| CN120884604A (zh) | 寡核苷酸组合物及其使用方法 | |
| WO2025043931A1 (zh) | 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物 | |
| BR112019017103A2 (pt) | conjugados liberáveis | |
| KR20220012284A (ko) | 핵산, 약학 조성물, 컨쥬게이트와 이의 제조 방법 및 용도 | |
| TW202039004A (zh) | 新穎脂肪酸及其於共軛至生物分子之用途 | |
| US20090175792A1 (en) | Glycomimetic inhibitors of siglec-8 | |
| CN104703996A (zh) | 新的rig-i配体及其生产方法 | |
| TW200836762A (en) | Polymeric short interfering RNA conjugates | |
| TW202340466A (zh) | 一種ｄｓｒｎａ、其製備方法及應用 | |
| TW202017574A (zh) | 寡核酸組合物及其製備方法 | |
| WO2024217504A1 (zh) | 缀合物及其应用和制备 | |
| TW202334424A (zh) | 一種ｄｓｒｎａ、其製備方法及應用 | |
| WO2024230763A1 (zh) | 一种新型的靶向化合物和核酸缀合物，及其用途 | |
| WO2025130549A1 (zh) | 一种靶向整合素αvβ6的配体、缀合物、组合物以及它们的用途 | |
| TW202339773A (zh) | 一種ｄｓＲＮＡ、其應用及製備方法 | |
| JP2025527979A (ja) | ３クラスターガラクトース系化合物、コンジュゲート、その調製方法、及び使用 | |
| WO2025139811A1 (zh) | 一种核酸缀合物、其制备方法和应用 | |
| WO2025236571A1 (zh) | 一种用于小核酸肝外递送的化合物及其应用 | |
| WO2025237408A1 (zh) | 修饰的核苷、包含其的双链rna分子及用途 | |
| JP2026508972A (ja) | 関節炎の処置、寛解、または防止のための化合物および方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |